研究者詳細 - 山田　武千代

研究等業績 - その他 - 山田　武千代

分割表示 71 件中 1 - 20 件目／全件表示 >>

18F-FDG-PET/CT can be used to predict distant metastasis in hypopharyngeal squamous cell carcinoma

Suzuki S.

Journal of Otolaryngology - Head and Neck Surgery ( Journal of Otolaryngology - Head and Neck Surgery ) 51 ( 1 ) 2022年12月

DOI

Galectin-10 as a Potential Biomarker for Eosinophilic Diseases

Tomizawa H.

Biomolecules ( Biomolecules ) 12 ( 10 ) 2022年10月

DOI

Quantification of Aspergillus fumigatus antigen Asp f 1 in airway tissue and allergic inflammation

Miyabe Y.

Allergy: European Journal of Allergy and Clinical Immunology ( Allergy: European Journal of Allergy and Clinical Immunology ) 77 ( 10 ) 3154 - 3156 2022年10月

DOI

残存聴力活用型人工内耳術後の使用状況と今後の課題

山田武千代, 椎名和弘, 高橋辰, 中澤操

ＡＵＤＩＯＬＯＧＹ　ＪＡＰＡＮ ( 一般社団法人日本聴覚医学会 ) 65 ( 5 ) 347 - 347 2022年09月

DOI CiNii Research

GPNMB-Positive Cells in Head and Neck Squamous Cell Carcinoma—Their Roles in Cancer Stemness, Therapy Resistance, and Metastasis

Kawasaki Y.

Pathology and Oncology Research ( Pathology and Oncology Research ) 28 2022年08月

DOI

Irradiated fibroblasts increase interleukin-6 expression and induce migration of head and neck squamous cell carcinoma

Suzuki S.

PLoS ONE ( PLoS ONE ) 17 ( 1 January ) 2022年01月

DOI

Elevated Serum Leptin Levels in Patients With Eosinophilic Chronic Rhinosinusitis

Imoto Y.

Frontiers in Pharmacology ( Frontiers in Pharmacology ) 12 2022年01月

DOI

Allergic fungal diseases in the upper and lower airways

Ueki S.

ERS Monograph ( ERS Monograph ) 2022 119 - 140 2022年

DOI

Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab

Suzuki S.

Cancer Management and Research ( Cancer Management and Research ) 14 3293 - 3302 2022年

DOI

Executive summary: Japanese guidelines for allergic rhinitis 2020

Okano M.

Allergology International ( Allergology International ) 2022年

DOI

A case of Bow hunter’s syndrome due to cervical rotation and vertebral artery dissection

Koizumi K.

Equilibrium Research ( Equilibrium Research ) 81 ( 4 ) 199 - 205 2022年

Bow hunter's syndrome is a form of vertebrobasilar insufficiency in which cervical rotation causes mechanical occlusion or stenosis of the vertebrobasilar artery, resulting in various symptoms, including dizziness, vertigo, and/or syncope. We report a case of Bow hunter's syndrome in which cervical rotation caused dizziness and nystagmus.　A 45-year-old woman presented to our hospital complaining of experiencing vertigo and nausea when twisting her neck. Nystagmus testing using Frenzel goggles revealed nystagmus during right cervical rotation. There was no hearing loss. Magnetic resonance imaging (MRI) showed no evidence of cerebral infarction; however, basi-parallel anatomical scanning MRI revealed arterial dissection in the left vertebral artery more peripherally than beyond the branching off of the posterior inferior cerebellar artery. Cervical ultrasonography and vertebral angiography confirmed that the patient experienced vertigo due to lack of blood flow in the proximal portion of the left vertebral artery when she rotated her neck 90 degrees to the right.　Neurosurgeons at our institution performed neurosurgical C1-C2 posterior fixation, which led to complete resolution of her symptoms.　The pathogenesis of Bow hunter's syndrome can take many distinct patterns, and the direction of cervical rotation does not always correspond to the side of the symptoms. To diagnose Bow hunter's syndrome, it is important to positively identify the onset of symptoms during cervical rotation and perform appropriate imaging studies.

DOI CiNii Research

Clinical Efficacy of Omalizumab in 5 Patients with Japanese Cedar Seasonal Allergic Rhinitis in 2020 Who Were Given the Drug Again in 2021

Sato T.

Practica Oto-Rhino-Laryngologica ( Practica Oto-Rhino-Laryngologica ) 15 ( 9 ) 765 - 769 2022年

The incidence of allergic rhinitis caused by Japanese cedar pollen has been increasing in recent years. Treatment of seasonal allergic rhinitis includes oral treatment centered on second-generation antihistamines, topical steroid sprays, sublingual immunotherapy, etc. In addition, omalizumab, an anti-IgE antibody preparation, was approved in December 2019 for use in patients with severe or very severe symptoms who show inadequate response to existing treatments. During the 2020 cedar pollinosis season, which was the first cedar pollen season in Japan after the approval of omalizumab, we treated some patients with cedar pollen-induced seasonal allergic rhinitis with omalizumab at our hospitals. We report the clinical effects of the drug administered during the pollen season in 2020 and the effects of re-administration of the drug again in 2021 in patients with Japanese cedar pollinosis.In 2020, omalizumab was administered to 4 patients with severe symptoms and 1 patient with very severe symptoms. One of the patients received the drug for 2 weeks, while the remaining four patients received the drug for 4 weeks. All the patients showed improvement of symptoms after treatment, as compared to the symptom severity before the start of treatment. Of the 5 patients, 4 requested omalizumab treatment again in 2021, so that 80% were re-administered the drug in 2021. These patients received omalizumab statically significant earlier in 2021 as compared to 2020 (p = 0.014: Mann-Whitney U test). Only one of the patients also received sublingual immunotherapy. Even patients receiving sublingual immunotherapy could show severe allergic symptoms during the cedar pollinosis season, and omalizumab was effective even in the patient who showed symptoms while receiving sublingual immunotherapy at our hospital. Even when omalizumab treatment was started from the middle of the Japanese cedar pollen season, the intranasal findings improved after 2 weeks. Assessment of two patients with intranasal findings by the Japanese Rhinoconjunctivitis Quality of Life Questionnaire confirmed improvement of the nasal symptoms in patients who were treated with omalizumab. Omalizumab appears to be a useful drug for seasonal allergic rhinitis, but further studies are needed to confirm the findings.

DOI CiNii Research

Tumor Infiltrating Lymphocytes are Prognostic Factors and Can Be Markers of Sensitivity to Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma

Suzuki H.

Asian Pacific Journal of Cancer Prevention ( Asian Pacific Journal of Cancer Prevention ) 23 ( 4 ) 1271 - 1278 2022年

DOI

鼻茸組織内アスペルギルス抗原の同定とアレルギー・好酸球性炎症

宮部結, 山田武千代

日本鼻科学会会誌 ( 日本鼻科学会 ) 61 ( 1 ) 240 - 241 2022年

DOI CiNii Research

Investigation of Cry J1 and Cry J2 Concentrations in Japanese Cedar Pollen and Non-Pollen Seasons

Tomizawa H.

Iranian Journal of Public Health ( Iranian Journal of Public Health ) 51 ( 3 ) 705 - 707 2022年